Article
Correlation of TP53 and MDM2 genotypes and clinical outcome in platinum-treated head and neck cancer patients with more than 10 years' follow-up.
The International journal of biological markers - 28 May 2016
Vivenza Daniela, Monteverde Martino, Lattanzio Laura, Tonissi Federica, Astesana Valentina, Denaro Nerina, Comino Alberto, Russi Elvio, Lo Nigro Cristiana, Merlano Marco
Abstract excerpt
PURPOSE: Adequate biomarkers are still required to optimize therapy in patients with locally advanced head and neck squamous carcinomas (HNSCC) treated with chemoradiotherapy (CRT). METHODS: We updated the follow-up of 66 HNSCC patients treated with CRT we described more than 10 years ago, focusing on SNP Arg/Pro (R/P) at codon 72 and somatic mutations in TP53 and on SNP309 in the MDM2 gene. RESULTS: In wild-type...
Topics
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Carcinoma, Squamous Cell
- Female
- Follow-Up Studies
- Genotype
- Head and Neck Neoplasms
